Mechanisms of heparanase inhibitors in cancer therapy.

The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82

Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem (1999) 11.87

Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci U S A (1988) 5.52

Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med (1999) 4.22

Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol (2006) 3.24

Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol (2011) 2.69

Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst (2004) 2.52

B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul (1989) 2.40

The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol (2005) 2.31

Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem (2007) 2.25

Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest (2001) 2.18

Heparanase: busy at the cell surface. Trends Biochem Sci (2009) 2.07

The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials. J Thromb Haemost (2014) 2.07

Heparanase as mediator of angiogenesis: mode of action. FASEB J (2001) 2.04

Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res (2006) 2.02

The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells. J Cell Biol (2004) 1.91

Mammalian heparanase: what is the message? J Cell Mol Med (2007) 1.91

Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci (2004) 1.82

High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res (2003) 1.81

Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem (2004) 1.78

Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis. Matrix Biol (2004) 1.75

Human heparanase. Purification, characterization, cloning, and expression. J Biol Chem (1999) 1.69

Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood (2002) 1.69

Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res (1999) 1.69

Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. Science (1983) 1.63

Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood (2010) 1.61

Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost (2004) 1.59

Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun (2000) 1.59

Heparanase Enhances Tumor Growth and Chemoresistance by Promoting Autophagy. Cancer Res (2015) 1.59

Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J (2010) 1.58

Cloning and functional expression of a human heparanase gene. Biochem Biophys Res Commun (1999) 1.56

Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res (2003) 1.54

Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood (2000) 1.54

Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol (2000) 1.52

Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J Cell Biol (2005) 1.51

Structural characterization of human heparanase reveals insights into substrate recognition. Nat Struct Mol Biol (2015) 1.48

Significance of heparanase in cancer and inflammation. Cancer Microenviron (2011) 1.46

A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene (2005) 1.43

SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res (2011) 1.40

Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. J Biol Chem (2007) 1.35

Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res (2008) 1.35

Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer (2008) 1.31

The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev (2011) 1.28

Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypican have distinct functions. J Biol Chem (1998) 1.27

PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer (2011) 1.27

Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem (2005) 1.27

Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate (2003) 1.26

Function of heparanase in prostate tumorigenesis: potential for therapy. Clin Cancer Res (2008) 1.25

Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest (2003) 1.25

PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost (2007) 1.24

The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J (2013) 1.24

M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS One (2011) 1.24

CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol (1999) 1.23

Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost (2006) 1.21

A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res (2006) 1.19

Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J Biol Chem (2010) 1.19

Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J Biol Chem (2010) 1.16

Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J Biol Chem (2011) 1.15

Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res (2005) 1.14

Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase. J Biol Chem (2005) 1.13

Heparanase protein and gene expression in bladder cancer. J Urol (2001) 1.13

Genomic organization and chromosome localization of the newly identified human heparanase gene. Gene (2000) 1.10

Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery (2002) 1.10

Tumorigenic and adhesive properties of heparanase. Semin Cancer Biol (2010) 1.10

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs (2007) 1.09

Heparan sulfate chains of syndecan-1 regulate ectodomain shedding. J Biol Chem (2012) 1.09

Antisense-mediated suppression of human heparanase gene expression inhibits pleural dissemination of human cancer cells. Cancer Res (2001) 1.09

Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis. J Surg Oncol (2004) 1.08

The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics. Front Oncol (2014) 1.08

Tumor suppressor p53 regulates heparanase gene expression. Oncogene (2006) 1.07

Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer (2001) 1.05

Epidermal growth factor-induced heparanase nucleolar localization augments DNA topoisomerase I activity in brain metastatic breast cancer. Mol Cancer Res (2010) 1.04

Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma. Br J Cancer (2002) 1.03

Effect of heparin and liver heparan sulphate on interaction of HepG2-derived transcription factors and their cis-acting elements: altered potential of hepatocellular carcinoma heparan sulphate. Biochem J (2000) 1.02

Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res (2007) 1.02

Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost (2009) 1.02

Syndecans shed their reputation as inert molecules. Sci Signal (2009) 1.02

The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Invest New Drugs (2009) 1.02

The potential of heparanase as a therapeutic target in cancer. Biochem Pharmacol (2014) 1.01

PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. Mol Cancer Ther (2013) 1.01

Inhibition of histone acetyltransferase by glycosaminoglycans. J Cell Biochem (2008) 1.00

Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res (2011) 1.00

Syndecan-1 expression--a novel prognostic marker in pancreatic cancer. Oncology (2005) 0.99

Structure modeling, ligand binding, and binding affinity calculation (LR-MM-PBSA) of human heparanase for inhibition and drug design. Proteins (2006) 0.98

Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer. Neoplasia (2015) 0.98

Heparanase expression and angiogenesis in endometrial cancer. Gynecol Obstet Invest (2003) 0.96

Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis. Clin Cancer Res (2003) 0.96

Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids? Clin Cancer Res (2007) 0.96

Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget (2016) 0.96

Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells. Thromb Haemost (2008) 0.95

Syndecan-2 regulates the migratory potential of melanoma cells. J Biol Chem (2009) 0.95

Suppression of endoplasmic reticulum stress-induced invasion and migration of breast cancer cells through the downregulation of heparanase. Int J Mol Med (2013) 0.94

Suramin. A potent inhibitor of melanoma heparanase and invasion. J Biol Chem (1991) 0.94

Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma. J Biol Chem (2012) 0.94

Syndecan-2 cytoplasmic domain regulates colon cancer cell migration via interaction with syntenin-1. Biochem Biophys Res Commun (2011) 0.93

Heparanase and platelet factor-4 induce smooth muscle cell proliferation and migration via bFGF release from the ECM. J Biochem (2002) 0.93

Antisense-mediated suppression of Heparanase gene inhibits melanoma cell invasion. Neoplasia (2005) 0.93

Downregulation of heparanase by RNA interference inhibits invasion and tumorigenesis of hepatocellular cancer cells in vitro and in vivo. Int J Oncol (2012) 0.93

Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance. J Med Chem (2003) 0.92

Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion. BMC Cancer (2009) 0.92